High serum uric acid levels are protective against cognitive impairment in amyotrophic lateral sclerosis.
Amyotrophic lateral sclerosis
Cognition
Frontotemporal dementia
Phenotype
Uric acid
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
25 Oct 2023
25 Oct 2023
Historique:
received:
05
09
2023
accepted:
09
10
2023
revised:
08
10
2023
medline:
26
10
2023
pubmed:
26
10
2023
entrez:
25
10
2023
Statut:
aheadofprint
Résumé
Uric acid (UA) has emerged as a factor that can modify cognitive function both in the general population and in people with neurodegenerative disorders. Since very few data are available concerning amyotrophic lateral sclerosis (ALS), we explored the correlation of UA levels and cognitive impairment in a large cohort of ALS patients. We enrolled ALS patients consecutively seen at the Turin ALS expert center in the 2007-2018 period who underwent both cognitive/behavioral and UA evaluation at diagnosis. Patients were classified in 5 categories: normal cognition (ALS-CN), isolated cognitive impairment (ALSci), isolated behavioural impairment (ALSbi), cognitive and behavioural impairment (ALScbi), frontotemporal dementia (ALS-FTD). For this study, ALSci, ALSbi and ALScbi were merged as ALS with intermediate cognitive impairment (ALS-INT). Out of the 841 ALS patients, 422 had ALS-CN, 271 ALS-INT and 148 ALS-FTD. The mean values of UA were significantly different among the cognitive subgroups of patients, with the lowest values in the ALS-FTD (ALS-CN, 288.5 ± 78.0 (μmol/L; ALS-INT, 289.7 ± 75.5 μmol/L; ALS-FTD, 271.8 ± 74.9 μmol/L; p = 0.046). The frequency of ALS-FTD was significantly higher in the 1st tertile of UA. Lower UA levels were independently associated with FTD (OR 1.32, 95% c.i. 1.01-1.43; p = 0.038) in binary logistic regression. We found that in ALS lower UA serum levels are correlated with reduced frequency of co-morbid FTD. Patients with intermediate cognitive impairment showed UA levels similar to ALS-CN but higher than ALS-FTD, implying that higher UA levels can prevent or delay cognitive function deterioration.
Sections du résumé
BACKGROUND
BACKGROUND
Uric acid (UA) has emerged as a factor that can modify cognitive function both in the general population and in people with neurodegenerative disorders. Since very few data are available concerning amyotrophic lateral sclerosis (ALS), we explored the correlation of UA levels and cognitive impairment in a large cohort of ALS patients.
METHODS
METHODS
We enrolled ALS patients consecutively seen at the Turin ALS expert center in the 2007-2018 period who underwent both cognitive/behavioral and UA evaluation at diagnosis. Patients were classified in 5 categories: normal cognition (ALS-CN), isolated cognitive impairment (ALSci), isolated behavioural impairment (ALSbi), cognitive and behavioural impairment (ALScbi), frontotemporal dementia (ALS-FTD). For this study, ALSci, ALSbi and ALScbi were merged as ALS with intermediate cognitive impairment (ALS-INT).
RESULTS
RESULTS
Out of the 841 ALS patients, 422 had ALS-CN, 271 ALS-INT and 148 ALS-FTD. The mean values of UA were significantly different among the cognitive subgroups of patients, with the lowest values in the ALS-FTD (ALS-CN, 288.5 ± 78.0 (μmol/L; ALS-INT, 289.7 ± 75.5 μmol/L; ALS-FTD, 271.8 ± 74.9 μmol/L; p = 0.046). The frequency of ALS-FTD was significantly higher in the 1st tertile of UA. Lower UA levels were independently associated with FTD (OR 1.32, 95% c.i. 1.01-1.43; p = 0.038) in binary logistic regression.
CONCLUSIONS
CONCLUSIONS
We found that in ALS lower UA serum levels are correlated with reduced frequency of co-morbid FTD. Patients with intermediate cognitive impairment showed UA levels similar to ALS-CN but higher than ALS-FTD, implying that higher UA levels can prevent or delay cognitive function deterioration.
Identifiants
pubmed: 37880536
doi: 10.1007/s00415-023-12056-8
pii: 10.1007/s00415-023-12056-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministero della Salute
ID : RF-2016-02362405
Organisme : Ministero dell'Istruzione, dell'Università e della Ricerca
ID : 2017SNW5MB
Organisme : Seventh Framework Programme
ID : 259867
Organisme : Horizon 2020 Framework Programme
ID : 101017598
Informations de copyright
© 2023. The Author(s).
Références
Goutman SA, Hardiman O, Al-Chalabi A, Chió A, Savelieff MG, Kiernan MC, Feldman EL (2022) Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurol 21(5):465–479. https://doi.org/10.1016/S1474-4422(21)00414-2 . (PMID: 35334234; PMCID: PMC9513754)
doi: 10.1016/S1474-4422(21)00414-2
pubmed: 35334234
pmcid: 9513754
Akçimen F, Lopez ER, Landers JE, Nath A, Chiò A, Chia R, Traynor BJ (2023) Amyotrophic lateral sclerosis: translating genetic discoveries into therapies. Nat Rev Genet 24(9):642–658. https://doi.org/10.1038/s41576-023-00592-y . (PMID: 37024676)
doi: 10.1038/s41576-023-00592-y
pubmed: 37024676
Mijailovic NR, Vesic K, Borovcanin MM (2022) The influence of serum uric acid on the brain and cognitive dysfunction. Front Psychiatry 22(13):828476. https://doi.org/10.3389/fpsyt.2022.828476 . (PMID: 35530021)
doi: 10.3389/fpsyt.2022.828476
Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1(5):293–299. https://doi.org/10.1080/146608200300079536 . (PMID: 11464847)
doi: 10.1080/146608200300079536
pubmed: 11464847
Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EG, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, Rankin KP, Johnson JK, Gorno-Tempini ML, Rosen H, Prioleau-Latham CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, Rossor MN, Warren JD, Fox NC, Galasko D, Salmon DP, Black SE, Mesulam M, Weintraub S, Dickerson BC, Diehl-Schmid J, Pasquier F, Deramecourt V, Lebert F, Pijnenburg Y, Chow TW, Manes F, Grafman J, Cappa SF, Freedman M, Grossman M, Miller BL (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134(Pt 9):2456–2477. https://doi.org/10.1093/brain/awr179 . (PMID: 21810890)
doi: 10.1093/brain/awr179
pubmed: 21810890
pmcid: 3170532
Strong MJ, Abrahams S, Goldstein LH, Woolley S, Mclaughlin P, Snowden J, Mioshi E, Roberts-South A, Benatar M, HortobáGyi T, Rosenfeld J, Silani V, Ince PG, Turner MR (2017) Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener 18(3–4):153–174. https://doi.org/10.1080/21678421.2016.1267768 . (PMID: 28054827)
doi: 10.1080/21678421.2016.1267768
pubmed: 28054827
pmcid: 7409990
Roche JC, Rojas-Garcia R, Scott KM, Scotton W, Ellis CE, Burman R, Wijesekera L, Turner MR, Leigh PN, Shaw CE, Al-Chalabi A (2012) A proposed staging system for amyotrophic lateral sclerosis. Brain 135(Pt 3):847–852. https://doi.org/10.1093/brain/awr351 . (PMID: 22271664)
doi: 10.1093/brain/awr351
pubmed: 22271664
pmcid: 3286327
Chiò A, Hammond ER, Mora G, Bonito V, Filippini G (2015) Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 86(1):38–44. https://doi.org/10.1136/jnnp-2013-306589 . (PMID: 24336810)
doi: 10.1136/jnnp-2013-306589
pubmed: 24336810
Hussein et al (2023) The impact of serum uric acid on the progression of amyotrophic lateral sclerosis in adults aged 18 and older: a systematic review. Cureus. https://doi.org/10.7759/cureus.42312
doi: 10.7759/cureus.42312
pubmed: 37868384
pmcid: 10585602
Bai J, Zhang X, Wang H, Yu W, He Z, Wang J, Feng F, Li M, Wang H, Yang F, Huang X (2023) Gender-specific association of uric acid and survival in sporadic amyotrophic lateral sclerosis patients. Brain Res 7(1815):148445. https://doi.org/10.1016/j.brainres.2023.148445 . (PMID: 37290609)
doi: 10.1016/j.brainres.2023.148445
Zhang Q, Li Q, Zhao H, Shu M, Luo M, Li Y, Ding Y, Shi S, Cheng X, Niu Q (2023) Neurodegenerative disease and antioxidant biomarkers: a bidirectional Mendelian randomization study. Front Neurol 23(14):1158366. https://doi.org/10.3389/fneur.2023.1158366 . (PMID: 37034095)
doi: 10.3389/fneur.2023.1158366
Şanlı BA, Whittaker KJ, Motsi GK, Shen E, Julian TH, Cooper-Knock J (2022) Unbiased metabolome screen links serum urate to risk of Alzheimer’s disease. Neurobiol Aging 120:167–176. https://doi.org/10.1016/j.neurobiolaging.2022.09.004 . (PMID: 36206691)
doi: 10.1016/j.neurobiolaging.2022.09.004
pubmed: 36206691
Parkinson Study Group SURE-PD3 Investigators, Schwarzschild MA, Ascherio A, Casaceli C, Curhan GC, Fitzgerald R, Kamp C, Lungu C, Macklin EA, Marek K, Mozaffarian D, Oakes D, Rudolph A, Shoulson I, Videnovic A, Scott B, Gauger L, Aldred J, Bixby M, Ciccarello J, Gunzler SA, Henchcliffe C, Brodsky M, Keith K, Hauser RA, Goetz C, LeDoux MS, Hinson V, Kumar R, Espay AJ, Jimenez-Shahed J, Hunter C, Christine C, Daley A, Leehey M, de Marcaida JA, Friedman JH, Hung A, Bwala G, Litvan I, Simon DK, Simuni T, Poon C, Schiess MC, Chou K, Park A, Bhatti D, Peterson C, Criswell SR, Rosenthal L, Durphy J, Shill HA, Mehta SH, Ahmed A, Deik AF, Fang JY, Stover N, Zhang L, Dewey RB Jr, Gerald A, Boyd JT, Houston E, Suski V, Mosovsky S, Cloud L, Shah BB, Saint-Hilaire M, James R, Zauber SE, Reich S, Shprecher D, Pahwa R, Langhammer A, LaFaver K, LeWitt PA, Kaminski P, Goudreau J, Russell D, Houghton DJ, Laroche A, Thomas K, McGraw M, Mari Z, Serrano C, Blindauer K, Rabin M, Kurlan R, Morgan JC, Soileau M, Ainslie M, Bodis-Wollner I, Schneider RB, Waters C, Ratel AS, Beck CA, Bolger P, Callahan KF, Crotty GF, Klements D, Kostrzebski M, McMahon GM, Pothier L, Waikar SS, Lang A, Mestre T (2021) Effect of urate-elevating inosine on early Parkinson disease progression: the SURE-PD3 randomized clinical trial. JAMA 326(10):926–939. https://doi.org/10.1001/jama.2021.10207 . (PMID: 34519802)
doi: 10.1001/jama.2021.10207
Walk D, Nicholson K, Locatelli E, Chan J, Macklin EA, Ferment V, Manousakis G, Chase M, Connolly M, Dagostino D, Hall M, Ostrow J, Pothier L, Lieberman C, Gelevski D, Randall R, Sherman AV, Steinhart E, Walker DG, Walker J, Yu H, Wills AM, Schwarzschild MA, Beukenhorst AL, Onnela JP, Berry JD, Cudkowicz ME, Paganoni S (2023) Randomized trial of inosine for urate elevation in amyotrophic lateral sclerosis. Muscle Nerve 67(5):378–386. https://doi.org/10.1002/mus.27807 . (PMID: 36840949)
doi: 10.1002/mus.27807
pubmed: 36840949
Tang J, Yang Y, Gong Z, Li Z, Huang L, Ding F, Liu M, Zhang M (2021) Plasma uric acid helps predict cognitive impairment in patients with amyotrophic lateral sclerosis. Front Neurol 6(12):789840. https://doi.org/10.3389/fneur.2021.789840 . (PMID: 34938266; PMCID: PMC8685604)
doi: 10.3389/fneur.2021.789840
Chiò A, Moglia C, Canosa A, Manera U, D’Ovidio F, Vasta R, Grassano M, Brunetti M, Barberis M, Corrado L, D’Alfonso S, Iazzolino B, Peotta L, Sarnelli MF, Solara V, Zucchetti JP, De Marchi F, Mazzini L, Mora G, Calvo A (2020) ALS phenotype is influenced by age, sex, and genetics: a population-based study. Neurology 94(8):e802–e810. https://doi.org/10.1212/WNL.0000000000008869 . (PMID: 31907290)
doi: 10.1212/WNL.0000000000008869
pubmed: 31907290
Ames BN, Cathcart R, Schwiers E, Hochstein P (1981) Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 78(11):6858–6862. https://doi.org/10.1073/pnas.78.11.6858 . (PMID: 6947260)
doi: 10.1073/pnas.78.11.6858
pubmed: 6947260
pmcid: 349151
Squadrito GL, Cueto R, Splenser AE, Valavanidis A, Zhang H, Uppu RM, Pryor WA (2000) Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys 376(2):333–337. https://doi.org/10.1006/abbi.2000.1721 . (PMID: 10775420)
doi: 10.1006/abbi.2000.1721
pubmed: 10775420
Hooper DC, Scott GS, Zborek A, Mikheeva T, Kean RB, Koprowski H, Spitsin SV (2000) Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis. FASEB J 14(5):691–698. https://doi.org/10.1096/fasebj.14.5.691 . (PMID: 10744626)
doi: 10.1096/fasebj.14.5.691
pubmed: 10744626
Aliena-Valero A, Rius-Pérez S, Baixauli-Martín J, Torregrosa G, Chamorro Á, Pérez S, Salom JB (2021) Uric acid neuroprotection associated to IL-6/STAT3 signaling pathway activation in rat ischemic stroke. Mol Neurobiol 58(1):408–423. https://doi.org/10.1007/s12035-020-02115-w . (PMID: 32959172)
doi: 10.1007/s12035-020-02115-w
pubmed: 32959172
Glantzounis GK, Tsimoyiannis EC, Kappas AM, Galaris DA (2005) Uric acid and oxidative stress. Curr Pharm Des 11(32):4145–4151. https://doi.org/10.2174/138161205774913255 . (PMID: 16375736)
doi: 10.2174/138161205774913255
pubmed: 16375736
Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440(7081):237–241. https://doi.org/10.1038/nature04516 . (PMID: 16407889)
doi: 10.1038/nature04516
pubmed: 16407889
Spiga R, Marini MA, Mancuso E, Di Fatta C, Fuoco A, Perticone F, Andreozzi F, Mannino GC, Sesti G (2017) Uric acid is associated with inflammatory biomarkers and induces inflammation via activating the NF-κB signaling pathway in HepG2 cells. Arterioscler Thromb Vasc Biol 37(6):1241–1249. https://doi.org/10.1161/ATVBAHA.117.309128 . (PMID: 28408375)
doi: 10.1161/ATVBAHA.117.309128
pubmed: 28408375
Molshatzki N, Weinstein G, Streifler JY, Goldbourt U, Tanne D (2015) Serum uric acid and subsequent cognitive performance in patients with pre-existing cardiovascular disease. PLoS ONE 10(3):e0120862. https://doi.org/10.1371/journal.pone.0120862 . (PMID: 25794156)
doi: 10.1371/journal.pone.0120862
pubmed: 25794156
pmcid: 4368665
Euser SM, Hofman A, Westendorp RG, Breteler MM (2009) Serum uric acid and cognitive function and dementia. Brain 132(Pt 2):377–382. https://doi.org/10.1093/brain/awn316 . (PMID: 19036766)
doi: 10.1093/brain/awn316
pubmed: 19036766
Wu Y, Zhang D, Pang Z, Jiang W, Wang S, Tan Q (2013) Association of serum uric acid level with muscle strength and cognitive function among Chinese aged 50–74 years. Geriatr Gerontol Int 13:672–677. https://doi.org/10.1111/j.1447-0594.2012.00962.x
doi: 10.1111/j.1447-0594.2012.00962.x
pubmed: 23170844
Xiu S, Zheng Z, Guan S, Zhang J, Ma J, Chan P (2018) Serum uric acid and impaired cognitive function in community-dwelling elderly in Beijing. Neurosci Lett 637:182–187. https://doi.org/10.1016/j.neulet.2016.11.013 . (PMID: 27890742)
doi: 10.1016/j.neulet.2016.11.013
Geng R, Zhang Y, Liu M, Deng S, Ding J, Zhong H, Tu Q (2022) Elevated serum uric acid is associated with cognitive improvement in older American adults: a large, population-based-analysis of the NHANES database. Front Aging Neurosci 8(14):1024415. https://doi.org/10.3389/fnagi.2022.1024415 . (PMID: 36570535)
doi: 10.3389/fnagi.2022.1024415
Li Q, Cen K, Cui Y, Feng X, Hou X (2023) Uric acid levels and their association with vascular dementia and Parkinson’s disease dementia: a meta-analysis. Neurol Sci 44(6):2017–2024. https://doi.org/10.1007/s10072-023-06620-3 . (PMID: 36690824)
doi: 10.1007/s10072-023-06620-3
pubmed: 36690824
Qiao M, Chen C, Liang Y, Luo Y, Wu W (2021) The influence of serum uric acid level on Alzheimer’s disease: a narrative review. Biomed Res Int 2(2021):5525710. https://doi.org/10.1155/2021/5525710 . (PMID: 34124244)
doi: 10.1155/2021/5525710
Crockford C, Newton J, Lonergan K, Chiwera T, Booth T, Chandran S, Colville S, Heverin M, Mays I, Pal S, Pender N, Pinto-Grau M, Radakovic R, Shaw CE, Stephenson L, Swingler R, Vajda A, Al-Chalabi A, Hardiman O, Abrahams S (2018) ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS. Neurology 91(15):e1370–e1380. https://doi.org/10.1212/WNL.0000000000006317 . (PMID: 30209236)
doi: 10.1212/WNL.0000000000006317
pubmed: 30209236
pmcid: 6177274
Chiò A, Moglia C, Canosa A, Manera U, Vasta R, Brunetti M, Barberis M, Corrado L, D’Alfonso S, Bersano E, Sarnelli MF, Solara V, Zucchetti JP, Peotta L, Iazzolino B, Mazzini L, Mora G, Calvo A (2019) Cognitive impairment across ALS clinical stages in a population-based cohort. Neurology 93(10):e984–e994. https://doi.org/10.1212/WNL.0000000000008063 . (PMID: 31409738)
doi: 10.1212/WNL.0000000000008063
pubmed: 31409738
pmcid: 6745732